Welcome to our dedicated page for Progyny SEC filings (Ticker: PGNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Progyny, Inc. filings document public-company reporting for its Nasdaq-listed common stock and its women's health and family building benefits business. Recent Form 8-K reports furnish quarterly and annual financial results, guidance updates, Regulation FD materials, supplemental earnings presentations, and other material-event disclosures.
The company's proxy materials cover annual meeting governance, director and executive compensation, equity award information, and related shareholder voting matters. Other filings address executive employment and compensatory arrangements, as well as a derivative-action settlement notice tied to historical non-employee director compensation practices.
Progyny, Inc. (PGNY) reported an insider equity transaction by its Chief Executive Officer and director. The filing shows the settlement of previously earned performance stock units and related tax withholding.
On November 10, 2025, the reporting person acquired 125,000 shares of common stock at $0 upon settlement of PSUs that vested on October 31, 2025, after certification of performance. On the same date, 63,813 shares were withheld to cover taxes at a price of $22.37 per share. Following these transactions, the filer beneficially owned 600,751 shares directly, plus 1 share held indirectly.
Progyny, Inc. (PGNY) reported stronger Q3 2025 results. Revenue rose to $313.3M from $286.6M, with gross profit of $72.8M. Operating income increased to $21.5M and net income reached $13.9M, or $0.15 diluted EPS. For the first nine months, revenue was $970.3M and net income was $46.0M, reflecting solid year-to-date performance.
Liquidity remained healthy: cash and cash equivalents were $134.0M and marketable securities were $211.2M at quarter end. Operating cash flow for the nine months was $156.0M. The company entered a $200M revolving credit facility maturing in 2030, with no borrowings outstanding, and later authorized a new $200M share repurchase program in November 2025. Total assets were $795.2M and stockholders’ equity was $560.0M. As of October 31, 2025, 86,211,654 common shares were outstanding.
Client base and utilization supported growth: Q3 fertility benefits revenue was $201.9M and pharmacy benefits revenue was $111.4M. The company closed the Benefit Bump acquisition for $10.5M to extend family support offerings.
Progyny (PGNY) furnished an update on its latest results. The company announced financial results for the fiscal quarter ended September 30, 2025 and made these materials available to investors.
A press release and a supplemental earnings presentation were furnished as Exhibit 99.1 and Exhibit 99.2, respectively, and are also accessible via the investor relations site. The information furnished under Items 2.02 and 7.01, including these exhibits, is provided as furnished, not filed.
Progyny, Inc. director and Executive Chairman David J. Schlanger reported a sale of 1,893 shares of Progyny common stock on 10/01/2025 at a price of $21.52 per share. After the transaction, the filing shows he beneficially owns 220,419 shares, held directly. The filing states the shares sold were withheld to cover taxes upon the vesting of restricted stock units granted to the reporting person. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Progyny director and Chief Executive Officer Peter Anevski reported an insider transaction dated 10/01/2025. The Form 4 shows 7,977 shares of Progyny common stock were disposed of at a price of $21.52 per share, with the filer retaining beneficial ownership of 539,564 shares following the transaction. The filing explains the sale resulted from shares withheld to cover taxes on vested restricted stock units and notes the remaining reportable shares are held directly by PECO ANEVSKI 2020 SD LLC. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Progyny, Inc. (PGNY) insider Allison Swartz, EVP and General Counsel, reported two transactions on 09/04/2025. 339 shares were withheld to satisfy taxes on vested restricted stock units at a per-share value of $23.54, and 599 shares were sold at $23.53 under a Rule 10b5-1 trading plan entered May 13, 2025. The filings show 78,006 shares beneficially owned after the withholding event and 77,407 shares after the sale, reflecting a net reduction in direct holdings. The Form 4 was signed by an attorney-in-fact on 09/05/2025.
Michael E. Sturmer, President and director of Progyny, Inc. (PGNY), reported a sale of 7,977 shares of common stock on 09/04/2025 at a price of $23.54 per share. After the transaction he beneficially owned 296,658 shares. The filing is coded F(1) and explains the shares were withheld to satisfy tax withholding on vested restricted stock units. The Form 4 was signed by an attorney-in-fact on 09/05/2025.
Mark S. Livingston, the Chief Financial Officer of Progyny, Inc. (PGNY), reported a routine withholding of shares to cover taxes on vested restricted stock units. On 09/04/2025 he disposed of 479 shares of Progyny common stock at a price of $23.54 per share under transaction code F(1), which the filer explains represents shares withheld to satisfy withholding taxes upon RSU vesting. After the withholding, the reporting person beneficially owned 69,661 shares, held directly. The Form 4 is signed by the reporting person on 09/05/2025.
Form 144 filing for Progyny, Inc. (PGNY) reports a proposed sale of 599 shares of common stock through Fidelity Brokerage Services on 09/04/2025 with an aggregate market value of $14,094.47. The filing shows these shares were acquired the same day as restricted stock vesting and were paid as compensation. The issuer has 85,982,409 shares outstanding. The filing also discloses a prior sale by the same person: 2,398 shares sold on 08/28/2025 for $55,058.08, identified as seller Allison C. Swartz. The form includes the standard signature representation that the seller is not aware of undisclosed material adverse information.
Michael E. Sturmer, President and a director of Progyny, Inc. (PGNY), reported a non-discretionary disposition of 448 shares of Progyny common stock on 09/02/2025 at a reported price of $23.67 per share. The filing explains the shares were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock units. After the withholding, Sturmer beneficially owned 304,635 shares, reported in a Form 4 filed by one reporting person and executed via attorney-in-fact on 09/03/2025. The report reflects a routine, tax-related transaction rather than an open-market discretionary sale.